Diaverum grows Kazakhstan presence with 10-clinic acquisition

Munich / Almaty, 7 September 2015 – Diaverum today announced the acquisition of the ID Senim chain of ten kidney centres in Kazakhstan. Diaverum now operates 19 clinics in the Republic of Kazakhstan having entered the country on 1 January this year with the acquisition of Nefros Asia.

The acquisition was signed with ID Senim on 7 August 2015 with the transaction formally completed on 1 September.

The ten new centres acquired by Diaverum in Kazakhstan are spread across five regions and are located in Taldykorgan, Kyzylorda, Schuchinsk, Temirtau, Kazaly, Zhezkazgan, Zhanakorgan, Saryagash, Balqash and Kaskelen.

Diaverum CEO, Dag Andersson, commented that this new acquisition is a signal of Diaverum’s “long-term commitment” to Kazakhstan. “With this acquisition we underline that our mid- to long-term view for Kazakhstan is very positive despite the macroeconomic challenges the country is currently facing due to the low oil price. We will continue to invest in Kazakhstan and contribute to improving the quality of care for renal patients,” states Dag Andersson.

Kazakhstan’s Country Managing Director for Diaverum, Sardar Sadykov, explains the integration work begins now and will be the focus for the next six to twelve months. “We will place the emphasis on welcoming the incoming staff and patients to Diaverum and ensuring they feel at home with us. We will work together with the new clinic teams to further improve the medical quality delivered to our patients,” says Sardar Sadykov.

Måns Olsson, Diaverum’s Head of Area Middle East & Asia, says he is very pleased with this latest acquisition and excited that even more patients in Kazakhstan will receive Diaverum’s high-quality renal care. “Centres that are acquired by Diaverum have a significant, demonstrable improvement in medical outcomes — proof that we really do improve the quality of life for renal patients — and we will continue looking for investment opportunities in Kazakhstan and across the Middle East and Asia,” adds Måns Olsson.

The Republic of Kazakhstan is a transcontinental country in Central Asia, with its smaller European part west of the Ural River. Covering 2.7M square kilometres it is the ninth largest country in the world, with a total population of 18 million people. Worldwide, more than three million people suffer from end-stage renal disease (ESRD). In Kazakhstan, renal disease presents a large challenge with strong growth in the number of patients needing renal replacement therapy. In 2013, approximately 2,100 dialysis patients were in need of renal replacement therapy. By the end of 2014 this figure had risen to approximately 3,800 patients.